RxDoctor Payments Data

Carey Lindemann, MD

Family Medicine · Nacogdoches, TXNPI 1851543888

Payments from drug & device makers

$1,049in general payments, 2019–2025

Across 45 payments — averaging $23.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$250
  • Pfizer$221
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$130
  • Sanofi-aventis U.S. LLC$127
  • Avanir Pharmaceuticals, Inc.$126
  • Currax Pharmaceuticals LLC$50
  • plus $145 from 7 others

What the payments were for

  • Food & beverage$99995%
  • Education$505%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,049 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$72,487
Medicare patients
246
Services billed
994

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide236$253,102
EliquisApixaban519$208,908
JardianceEmpagliflozin400$158,513
MounjaroTirzepatide166$158,333
TrulicityDulaglutide117$95,301
LinzessLinaclotide75$68,550
MyrbetriqMirabegron176$67,708
RexultiBrexpiprazole51$64,828
Trelegy ElliptaFluticasone/Umeclidin/Vilanter86$61,659
JanuviaSitagliptin Phosphate89$55,811
FarxigaDapagliflozin Propanediol76$50,517
XareltoRivaroxaban86$35,976
EntrestoSacubitril/Valsartan78$31,375
VraylarCariprazine Hcl18$26,967
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog29$24,312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$221$208,908519 claims
AbbVieLinzess, Vraylar$15$95,51693 claims
Astellas Pharma US IncMyrbetriq$15$67,708176 claims
MerckJanuvia$31$55,81189 claims
NovartisEntresto$15$31,37578 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$130$24,22215 claims
Avanir Pharmaceuticals, Inc.Nuedexta$126$22,24153 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$127$16,52314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Nacogdoches

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →